SCHEMBL9939468

SCHEMBL9939468

CCOC(=O)c1cnc(CCl)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.55
DBF4 Q9UBU7 3/20 0.55
SLC5A2 P31639 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HCRTR2 O43614 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
OGA O60502 1/20 0.38
LMNA P02545 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912617 0.87 CDC7 (0.57) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL3843901 0.85 CDC7 (0.56) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL1646493 0.84 CDC7 (0.55) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL5911684 0.84 CDC7 (0.55) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL4989265 0.84 CDC7 (0.55) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL11705050 0.83 CDC7 (0.54) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL15896622 0.83 CDC7 (0.54) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL3162147 0.81 CDC7 (0.52) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL28267334 0.81 CDC7 (0.52) CDC7DBF4SLC5A2HDAC3HDAC4
SCHEMBL21199675 0.80 CDC7 (0.51) CDC7DBF4SLC5A2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651413-B1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES PHARMAHUNGARY 2000 KFT (HU) 2017-11-22 EP disclosed
US-9487462-B2 Inhibitors of matrix metalloproteinases PHARMAHUNGARY 2000 KFT. (HU) 2016-11-08 US disclosed
US-20130303572-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES TARGETEX KFT. (HU) 2013-11-14 US disclosed
EP-2651413-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES Pharmahungary 2000 Kft. (HU) 2013-10-23 EP disclosed
WO-2012080762-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES PHARMAHUNGARY 2000 KFT. (HU) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303572-A1 NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES TIMP3, MMP3, MMP13 CDC7 4838/4885DBF4 4165/4885SLC5A2 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.